The Danish m-health company Monsenso, has received a Class I medical-device certification from the Australian Register of Therapeutic Goods Administration (TGA) for its mobile-based solution for treatment of mental health. The certification indicates that the solution meets the essential requirements stipulated by the Australian Register of Therapeutic Administration.
Monsenso’s solution supports the treatment of behavioral disorders such as bipolar disorder, schizophrenia, depression, borderline personality disorder, and anxiety. It is a so-called double-loop solution based on two main concepts, monitoring and treatment. It monitors the patient through patient self-assessment and vital signs and notifies the care giver in case of deterioration in the patient’s psychological state. Furthermore, it supports treatment by offering customized action plans to help patients recognize and deal with difficult situations and ‘triggers’ while providing care givers with a history of the patient’s health, enabling them to give a more coherent treatment.
Monsenso’s certification was obtained with funding from the Danish Market Development Fund.
Read more here